Adverum Biotechnologies (ADVM) H.C. Wainwright 4th Annual Ophthalmology Virtual Conference summary

Key program updates and clinical insights

• Presented long-term efficacy and safety data for intravitreal gene therapy in wet AMD, with over half of patients functionally cured and free of injections for years.

• The proprietary 7m8 vector enables outpatient administration and robust, durable aflibercept expression, with stable levels measured for over 3.5 years.

• Phase 2 LUNA trial interim analysis showed 76% of high-burden patients were injection-free at 26 weeks, with 90% reduction in annualized anti-VEGF injections at the 6E10 dose.

• RMAT and PRIME designations facilitate regulatory engagement and may accelerate pivotal trial timelines, with Phase 3 design updates expected in Q4.

• Patient preference data revealed 88% preferred gene therapy over prior treatments, and 93% would want it in the other eye, highlighting quality-of-life improvements.

Safety, dosing, and prophylactic regimen

• Long-term data show minimal or no inflammation in most patients, with 93% inflammation-free at year 1 and 100% at year 2 in the OPTIC trial.

• Locally administered corticosteroid eye drops (difluprednate) are effective for managing immune response, eliminating the need for oral steroids.

• The 6E10 dose is selected for Phase 3, balancing efficacy and safety, with a tenfold safety margin established.

• Inflammation is typically mild, anterior, and easily managed; long-term safety continues to improve as inflammation wanes over time.

• Final Phase 3 prophylactic regimen and trial design will be announced in Q4, aiming for a non-inferiority study with BCVA as the primary endpoint.

Market opportunity, patient impact, and strategic outlook

• Gene therapy offers a transformative reduction in treatment burden, especially for elderly patients with limited mobility and high injection frequency.

• Medicare Part B covers most wet AMD patients, and gene therapy could yield significant cost savings by reducing the need for chronic anti-VEGF injections.

• Each percentage point of market share could represent $350 million in annual revenue, with 3% penetration equating to $1 billion.

• The product profile is designed for broad adoption, with a focus on patient preference, ease of administration, and payer education.

• Long-term follow-up from OPTIC confirms durable efficacy and safety, supporting the high bar for gene therapy in wet AMD.